Global Cord Blood Corp. (Hong Kong SAR, China)

The Company is principally engaged in the provision of umbilical cord blood storage and ancillary services in the People's Republic of China (the “PRC”).
HISTORY
The Company is a Cayman Islands company registered by way of continuation in the Cayman Islands on June 30, 2009.
On March 16, 2018, the company changed its name to Global Cord Blood Corp.
The Company s principal executive offices is at 48th Floor, Bank of China Tower, 1 Garden Road, Central, Hong Kong S.A.R.
On November 19, 2009, the Company was listed on the NYSE with a ticker symbol “CO”.
BUSINESS
The Company provides cord blood testing and processing services and storage services under the direction of subscribers for a cord blood processing fee and a storage fee. The Group also tests, processes and stores donated cord blood, and provides matching services to the public for a fee. As of March 31, 2021, the Group operates three cord blood banks, one in the Beijing municipality, one in the Guangdong province and one in the Zhejiang province, the PRC.
The Company is provider of cord blood banking services in China. The Company provide cord blood processing and storage services for expectant parents interested in capturing the opportunities made available by evolving medical treatments and technologies such as cord blood transplants. It also preserve cord blood units donated by the public, provide matching services on such donated units and deliver matching units to patients in need of transplants. Its Beijing-based subsidiary, Jiachenhong, was the operator of the first licensed cord blood bank in China.
The Company s operations currently benefit from multiple exclusive cord blood banking licenses issued in China, including its licenses for Beijing, Guangdong and Zhejiang. The Company also has a 24.0 equity interest in Qilu (its controlling shareholder owns the remaining 76.0 ), the operator of the exclusive licensed cord blood bank in the Shandong province.
The Company s cord blood banking network is the largest in China. The aggregate number of births in our operating regions, namely Beijing, Guangdong and Zhejiang, was estimated to be over 2.2 million in 2019, accounting for approximately 49 of the total newborn population in the seven provinces and municipalities that have been authorized or issued cord blood banking licenses to date, according to the China Statistical Yearbook 2020.
The Company has one operating segment.